Moolec Science, valued over $1B, calls shareholder vote on liquidation

Moolec Science, a biotech firm that indirectly took control of bankrupt Bioceres SA, will hold an assembly on October 20 to vote on a liquidation proposal. The move signals a potential collapse of a company previously valued at over US$1 billion, raising questions about its financial viability and the fate of its assets. The outcome is uncertain pending shareholder approval.